Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Net Cash Flow (2016 - 2025)

Lineage Cell Therapeutics' Net Cash Flow history spans 16 years, with the latest figure at $167000.0 for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 99.07% year-over-year to $167000.0; the TTM value through Dec 2025 reached -$5.4 million, down 151.89%, while the annual FY2025 figure was -$5.4 million, 151.89% down from the prior year.
  • Net Cash Flow reached $167000.0 in Q4 2025 per LCTX's latest filing, up from -$1.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $23.6 million in Q1 2021 to a low of -$45.4 million in Q3 2022.
  • Average Net Cash Flow over 5 years is $449150.0, with a median of -$515000.0 recorded in 2021.
  • The largest YoY upside for Net Cash Flow was 10633.18% in 2021 against a maximum downside of 6853.33% in 2021.
  • A 5-year view of Net Cash Flow shows it stood at -$5.1 million in 2021, then plummeted by 162.25% to -$13.3 million in 2022, then surged by 127.93% to $3.7 million in 2023, then skyrocketed by 385.8% to $18.0 million in 2024, then tumbled by 99.07% to $167000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Net Cash Flow are $167000.0 (Q4 2025), -$1.8 million (Q3 2025), and -$5.9 million (Q2 2025).